BeiGene, Ontada Announce Strategic Alliance to Develop RWE, Improve Access to Oncology Therapies

Biotechnology company BeiGene and Ontada, a McKesson Corporation business providing technology and real-world evidence (RWE), research, and education to oncology practices, announced a collaboration on August 15 to “improve US community oncology care through the development of real-world evidence data, tools, and insights to help increase access to affordable cutting-edge therapies.”

According to a joint statement from the companies, Ontada will lead the partnership, with a focus on the use of RWE to underscore the value of oncolytics and to improve patient access to oncology therapies. As part of the partnership, the companies will:

• Optimize the use of RWE to communicate value across key stakeholders including patients, providers, and payers;
• Develop timely education on emerging science and therapeutic differentiation; and
• Collaborate to advance use of RWE in health care and regulatory decision-making to improve patient access to oncology therapies.

Christiane Langer, MD, senior vice president of Global Medical Affairs (Ex-China) for BeiGene, said the company seeks to bring 10 molecules per year to the clinic starting in 2023. “As this research advances, we’re delighted to form this strategic partnership with McKesson, which shares the same vision as BeiGene for improving the care of cancer patients,” Langer said in the statement.

“This collaboration will leverage Ontada’s technology platform and deep understanding of the experiences of patients treated in community oncology clinics to help accelerate both the development of the BeiGene portfolio and expand access to treatment options.”

“Ontada is uniquely positioned to support complex research that uncovers deeper patient insights and perspectives that advance cancer care,” Susan Shiff, PhD, MBA, president of Ontada, said in the statement. “We are excited to announce this unique partnership with BeiGene and look forward to developing a stronger understanding of how to better treat oncology patients through the use of real-world data and evidence.”

“BeiGene is excited to work with Ontada to advance our shared vision of improving patient access, affordability, and value for community oncology stakeholders and key partners working at the intersection of clinical practice and real-world evidence,” said Josh Neiman, MBA, BeiGene’s chief commercial officer for North America and Europe. “Working together, BeiGene and Ontada will generate novel oncology insights through real-world data, tools, and technologies that will facilitate the acceleration of precise decision-making in support of community oncology practices whose ultimate mission is to improve patient outcomes.” 

Reference
BeiGene announces strategic alliance with Ontada to improve US community oncology care. News release. BeiGene. August 15, 2022. Accessed September 21, 2022. https://bit.ly/3f5Qxr4